Industry trade groups that would like rebates preserved in the Medicare Part D purchasing system were thrilled to see a Sept. 13 report from the HHS Office of Inspector General that they viewed as dispelling the oft-purported “myth” that rebates are responsible for high drug prices. But one industry expert says he doesn’t think this will alter any possible government action on drug pricing and Part D. Specifically, the report examining the more than 1,510 brand-name drugs with Part D reimbursement and rebates between 2011 and 2015 found that rebates did not always go up when unit reimbursement grew. Ninety-six percent of the drugs reviewed experienced increases in unit reimbursement, but for 39% of those drugs rebates dropped, estimated OIG.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.